Sorintellis, founded in 2022 and headquartered in Canada, is making significant strides in the pharmaceutical portfolio management (PPM) sector. Utilizing a groundbreaking AI-powered decision support system, this Montreal-based company seeks to tackle the complex issues associated with drug development, offering a transformative solution through explainable machine learning.
Their mission focuses on aiding pharmaceutical companies, contract research organizations (CROs), and life sciences mezzanine investment funds with sophisticated AI tools designed for due diligence and strategic scenario assessment. The company's unique drug development risk network (DDRNAi) technology is poised to provide integral insights, facilitating crucial "Go/No Go" decisions.
By streamlining drug clinical development, Sorintellis presents significant investment potential within the AI, Biotechnology, and Life Sciences industries, without any recent funding rounds disclosed.